Search results for "TX"

showing 10 items of 509 documents

Bioavailability of plant sterol-enriched milk-based fruit beverages: In vivo and in vitro studies

2015

Abstract This study for the first time compares the in vivo (response in serum from individuals of an interventional study) and in vitro effects (bioaccessibility determined from simulated gastrointestinal digestion) of two plant sterol (PS)-enriched milk-based fruit beverages (with and without tangerine fruit juice rich in β-cryptoxanthin (β-Cx)) in order to assess their suitability as PS-enriched food matrixes, and the possible interactions between the two bioactive compounds (β-Cx and PS) that might affect their absorption. The randomized, double-blind, crossover study (performed in 36 postmenopausal women) showed the β-sitosterol and campesterol serum concentrations after four weeks of …

Nutrition and DieteticsNutrition. Foods and food supplyCampesterolPhytosterolsMedicine (miscellaneous)Gastrointestinal digestionBioaccessibilityAbsorption (skin)Plant sterolCrossover studyIn vitroGastrointestinal digestionBioavailabilitychemistry.chemical_compoundchemistryIn vivoInterventional studyFunctional beveragesTX341-641Food scienceFood ScienceJournal of Functional Foods
researchProduct

La influencia de la nutrición en la industria alimentaria

2021

Nutrition and DieteticsRC620-627ChemistryNutrition. Foods and food supplynuevos alimentosTX341-641industria alimentarianutriciónNutritional diseases. Deficiency diseasesFood ScienceRevista Española de Nutrición Humana y Dietética
researchProduct

Spanish Journal of Human Nutrition and Dietetics editors Conflicts of Interest declaration 2020-2022

2020

Se reconoce como Conflicto de Interés (COI), al conjunto de condiciones en las que el juicio profesional en relación a un interés primario, tiende a ser indebidamente influenciado por un interés secundario (como por ejemplo el beneficio económico)1 . Esta situación no es ajena a los procesos editoriales de revistas científicas, estando presente desde la producción de manuscritos por los/as autores/as, la revisión por pares y las gestiones de los/as miembros de los equipos editoriales.

Nutrition and DieteticsRC620-627Nutrition. Foods and food supplyConflicto de InteresesConflict of InterestPolitical scienceMedicina Preventiva y Salud PúblicaTX341-641EnfermeríaNutritional diseases. Deficiency diseasesFood Science
researchProduct

Editorial decisions: highlighting the role of systematic reviews

2018

En 2014, el doctor Gerard Urrútia del Centro Cochrane Iberoamericano - Institut d'Investigació Biomèdica Sant Pau, escribió unas líneas editoriales para la Revista Española de Nutrición Humana y Dietética1 en las que ponía en valor la necesidad de "incrementar el rigor científico tanto en la producción de estudios científicos, que proporcionen las bases para una toma de decisiones bien fundamentada, como en su divulgación mediante publicaciones científicas de calidad" en el ámbito de la nutrición y la dietética. Asimismo vaticinaba que "cabría esperar, por una parte, un creciente interés en la producción de revisiones sistemáticas por parte de profesionales de nuestro medio, también entre d…

Nutrition and DieteticsRC620-627Nutrition. Foods and food supplyDecisiones editoriales03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicina Preventiva y Salud PúblicaTX341-641030212 general & internal medicinePsychologyNutritional diseases. Deficiency diseasesFood ScienceRevisiones sistemáticasRevista Española de Nutrición Humana y Dietética
researchProduct

Balance del año 2020 y nuevos propósitos de 2021 para abordar los objetivos propuestos en el Plan Estratégico 2020-2022 de la Revista Española de Nut…

2021

Nutrition and DieteticsRC620-627Nutrition. Foods and food supplyTX341-641EnfermeríaNutritional diseases. Deficiency diseasesFood ScienceRevista Española de Nutrición Humana y Dietética
researchProduct

Biosorption of green and black tea polyphenols into Saccharomyces cerevisiae improves their bioaccessibility

2015

Infusions of green tea (GT) and black tea (BT) and the use of Saccharomyces cerevisiae as a natural matrix were employed to check the impact of biosorption on the possible fate of tea polyphenols in the gastrointestinal tract in terms of bioaccessibility and total antioxidant capacity (TEAC and ORAC assays). The maximum biosorption yields obtained were 47.61 ± 11.57 and 99.68 ± 5.25 mg/g from GT and BT infusions, respectively. A significant increase (p < 0.05) in the recovery of phenolic compounds was shown after in vitro digestion. The bioaccessible fractions generally exhibited higher antioxidant capacities in both tea infusions and suspensions of S. cerevisiae versus non-digested samples…

Nutrition and DieteticsTeabiologyNutrition. Foods and food supplyChemistrySaccharomyces cerevisiaeORAC AssaysTotal antioxidant capacityBiosorptionPolyphenolsIn vitro gastrointestinal digestionfood and beveragesMedicine (miscellaneous)Saccharomyces cerevisiaebiology.organism_classificationGreen teaAntioxidant capacityPolyphenolBiosorptionBotanyTX341-641Food scienceBlack teaFood ScienceJournal of Functional Foods
researchProduct

Modulation of biotransformation and elimination systems by BM-21, an aqueous ethanolic extract from Thalassia testudinum, and thalassiolin B on human…

2012

Abstract BM-21 is an extract obtained from Thalassia testudinum marine plant with pharmacological properties. The effects of BM-21 and thalassiolin B (TB), its main component, on enzyme and transport proteins involved in drug metabolism and excretion in human cultured hepatocytes were evaluated. Cells were exposed for 48 h to sub-cytotoxic concentrations of BM-21 or TB. Effects on P450 isoforms revealed significant reductions of CYP1A2, 3A4 and 2D6 activities (up to 56%, 66% and 44% inhibition, respectively) after exposition to BM-21, no changes on CYP2A6 and 2C9 activities. TB produced a concentration-dependent reduction of all P450 activities. In addition, a decrease in total UGT and UGT2…

Nutrition and DieteticsbiologyCYP3A4Nutrition. Foods and food supplyThalassiolin BCYP1A2PolyphenolsMedicine (miscellaneous)Cytochrome P450Cytochrome P450P-glycoproteinPharmacologyExcretionBiotransformationIn vivobiology.proteinThalassia testudinumTX341-641UDP-glucuronosyltransferasesCYP2A6Drug metabolismFood ScienceJournal of Functional Foods
researchProduct

Food Frontiers : An academically sponsored new journal

2020

Nutrition. Foods and food supplybusiness.industryPolitical scienceTX341-641Food technologyTP368-456MarketingbusinessFood processing and manufactureFood Frontiers
researchProduct

Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.

2012

ABSTRACT Objective: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 ( ATXN-2 ) gene are a risk factor for amyotrophic lateral sclerosis (ALS). This work was undertaken with the aim to investigate the frequency of ataxin-1 ( ATXN-1 ) and ATXN-2 PolyQ expansions in a cohort of patients with sporadic ALS (sALS) and patients with familial ALS (fALS) from southern Italy. Methods: We assessed the PolyQ lengths of ATXN-1 and ATXN-2 in 405 patients with sALS, 13 patients with fALS, and 296 unrelated controls without history of neurodegenerative disorders. Results: We found significantly higher intermediate PolyQ expansions ≥32 for ATXN-1 alleles an…

OncologyAdultMalemedicine.medical_specialtyGenotypeALS; ATXN-1; ATXN-2Ataxin 1Nerve Tissue ProteinsRisk FactorsInternal medicinemedicineHumansIn patientGenetic Predisposition to DiseaseAmyotrophic lateral sclerosisAlleleRisk factorAge of OnsetATXN-2ATXN-1AllelesAtaxin-1AgedAged 80 and overbiologybusiness.industryAmyotrophic Lateral SclerosisAge FactorsNuclear ProteinsMiddle Agedmedicine.diseaseIncreased riskPOLYGLUTAMINE EXPANSIONS; HEXANUCLEOTIDE REPEAT; ALS; TYPE-1; NEURODEGENERATION; PHENOTYPE; GENETICS; PROTEIN; C9ORF72; RISKAtaxinsItalyAtaxinCohortbiology.proteinFemaleSettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessPeptidesTrinucleotide Repeat Expansion
researchProduct

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

2014

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost–effectiveness involved with the use of the drug.

OncologySettore MED/06 - Oncologia MedicaCost effectivenessColorectal cancercost-effectiveneCetuximabColorectal NeoplasmPharmacologyAntineoplastic AgentPhosphatidylinositol 3-KinasesMutational statusMedicineNeoplasm MetastasiscetxuximabProto-Oncogene ProteinTOR Serine-Threonine KinaseCetuximabPharmacogeneticTOR Serine-Threonine KinasesNeoplasm MetastasiErbB ReceptorsMolecular MedicineColorectal NeoplasmsHumanmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtypharmacogenomicEGFRAntineoplastic AgentsAntibodies Monoclonal HumanizedresistanceProto-Oncogene Proteins p21(ras)Geneticcolorectal carcinomaProto-Oncogene ProteinsInternal medicineGeneticsHumanspredictivecost-effectivenessneoplasmspharmacogenomicsPharmacologybusiness.industryPTEN Phosphohydrolaseras Proteinmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsMutationras ProteinsReceptor Epidermal Growth FactorPhosphatidylinositol 3-KinasebusinessProto-Oncogene Proteins c-aktPharmacogeneticsRASPharmacogenomics
researchProduct